c8

General Information


DRACP ID  DRACP00439

Peptide Name   c8

Sequence  KWXKK

Sequence Length  5

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Ramos Burkitt lymphoma; Burkitt lymphoma Lymphoma IC50=20±2 μM MTT assay Not available 1
Ramos Burkitt lymphoma; Burkitt lymphoma Lymphoma IC50=226±21 μM MTT assay Not available 1

Hemolytic Activity  Human red blood cells: EC50=298 μM

Normal (non-cancerous) Cytotoxicity  MRC-5: IC50=53±2 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  NCB: Lys1<--->Lys5

N-terminal Modification  lactam

C-terminal Modification  lactam

Other Modification  X=β2,2(2-Nal-CH2-)=(2,2-di(naphthalen-2-ylmethyl)-3-amino-propionic acid)

Chiral  L



Physicochemical Information


Formula  C29H46N8O4

Absent amino acids  ACDEFGHILMNPQRSTVY

Common amino acids  K

Mass  75226

Pl  11.1

Basic residues  3

Acidic residues  0

Hydrophobic residues  1

Net charge  3

Boman Index  -1432

Hydrophobicity  -252

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  5500

Absorbance 280nm  1375

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22933412

Title  Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β(2,2) -amino acid

Doi 10.1002/psc.2441

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.